Cerilliant Introduces New Certified Snap-N-Spike® Solutions of NBOMe

SAINT LOUIS, MO – June 5, 2014 – Sigma-Aldrich Corporation (NASDAQ: SIAL) is pleased to announce that the Cerilliant® brand within its Applied Diagnostics and Testing Business Unit has introduced six new certified Snap-N-Spike® solutions of designer psychedelics in the NBOMe (N-methoxybenzyl-substituted) class of phenethylamines. New products include 25I-NBOMe HCl, 25C-NBOMe HCl, and 25B-NBOMe HCl and their deuterium labeled internal standards.

NBOMe phenethylamine derivatives, street names "N-Bomb", "Smiles", "25I", "25C", "25B" represent a potentially lethal class of designer drugs with psychedelic and psychostimulant effects similar to LSD. Worldwide, increased production and sale of counterfeit hallucinogens laced with NBOMe derivatives have contributed to rising incidence of acute NBOMe toxicity.1,2 Individuals suffering from acute NBOMe toxicity have been reported to experience severe adverse health effects including metabolic acidosis, tachycardia, organ failure, and in some instances, death.3

Regulatory agencies are responding to the threat posed by the harmful effects and growing use of these new NBOMe designer drugs. In the fall of 2013, the US Drug Enforcement Administration (DEA) temporarily placed 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe into Schedule I of the Controlled Substances Act.4

Cerilliant’s latest NBOMe reference standards complement their current offering of Certified Spiking Solutions® for phenethylamines and their internal standards including the 2C amines, dibenzofurans, and D amphetamines. Since these compounds are classified as controlled substances, Cerilliant supplies its Certified Spiking Solutions® of NBOMe phenethylamines in a convenient, quantitative, USDEA and Health Canada (with TK#s)-exempt solution. Cerilliant’s reference standards are manufactured and certified to the highest industry standards including ISO Guide 34, ISO/IEC 17025, and ISO 13485 and are suitable for a wide variety of quantitative or qualitative applications from control or calibrator preparation in forensic analysis or clinical toxicology testing to urine drug analysis and isotope dilution methods.

About CerilliantCerilliant Corporation, located in Round Rock, Texas, is a global leader in providing certified reference standards for critical applications. The company has been providing certified reference materials for over 30 years. Cerilliant offers more than 3,000 catalog products and a full range of custom products and services that address the stringent and complex requirements of the pharmaceutical, clinical diagnostic, clinical/forensic toxicology, natural products industries. Cerilliant sustains a modern, robust quality system, which incorporates cGMP, GLP, and ISO requirements. We are accredited to ISO Guide 34 and ISO/IEC 17025, certified to ISO 13485 and ISO 9001:2008, and are compliant with ISO 17511 and ISO 15194. Cerilliant Corporation is a subsidiary of Sigma-Aldrich®. For more information about Cerilliant, please visit www.cerilliant.com.

About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and High Technology company focused on enhancing human health and safety, manufactures and distributes more than 200,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units – Research, Applied and SAFC Commercial – Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has more than 9,000 employees worldwide and had sales of $2.7 billion in 2013. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.Sigma-Aldrich and Cerilliant are registered trademarks of Sigma-Aldrich Co. LLC.

1)http://www.jsad.com/jsad/downloadarticle/The_NBOMe_Series_A_Novel_Dangerous_Group_of_Hallucinogenic_Drugs_OPEN_AC/5218.pdf2) https://theconversation.com/explainer-what-is-nbome-169503) http://informahealthcare.com/doi/abs/10.3109/15563650.2013.8027954) http://www.deadiversion.usdoj.gov/fed_regs/rules/2013/fr1115.htm